NICEVIVA
MONOGRAPH SPEC LATEST 2026

Pumpkin Seed Oil (Cucurbita pepo)

SKIN HAIR · Evidence Monograph

Pumpkin Seed Oil (Cucurbita pepo) is an evidence-graded skin hair monograph evaluated across 20 peer-reviewed PubMed studies (1 meta-analyses, 2 systematic reviews, and 3 randomized controlled trials, encompassing n = 255 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 20 Studies
Meta-Analyses · Reviews 1 Meta · 2 Systematic Reviews
Randomized Trials (RCT) 3 RCTs (1 Double-Blind)
Cumulative Participants n = 255
Reported Trial Dosages 30 g
Trial Duration Range 6 months · 3 months · 14 days
Reading Time ~10 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 20 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (30 g) over a structured 6 months evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
With Breakfast or Lunch
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
androgenetic alopecia (PubMed clinical endpoint)
alopecia (PubMed clinical endpoint)
hair (PubMed clinical endpoint)
01

What Is Pumpkin Seed Oil (Cucurbita pepo) & Why Does Form Matter?

Pumpkin Seed Oil (Cucurbita pepo) is classified under SKIN HAIR and has been investigated across 20 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (30 g).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Pumpkin Seed Oil (Cucurbita pepo) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (3 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Pumpkin Seed Oil (Cucurbita pepo) acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Pumpkin Seed Oil (Cucurbita pepo) an overall evidence rating of GRADE High (4.0 / 4.0) based on 20 PubMed studies: 1 meta-analyses, 2 systematic reviews, and 3 randomized controlled trials (1 double-blind, n = 255 total participants).

Representative peer-reviewed findings include: • PMID:42371524 (2026) — "Dutasteride-loaded nanostructured lipid carrier for androgenic alopecia treatment - An in vivo study." (Gamma-oryzanol (GO) is an anti-oxidant and anti-5-alpha reductase, which has been i) • PMID:41561175 (2025) — "Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis." (Dietary supplements, claimed to promote hair growth by inhibiting androgen pathways and improving the follicular microenvironment, have become an attractive adjunct for both clinicians and patients due to their low cost and ease of use.) • PMID:40853071 (2025) — "Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A Real-Life, Multicenter, Randomized, Assessor-Blinded Trial on 225 Subjects." (RESULTS: The results indicated that oral supplementation significantly increased the clinical efficacy of pharmacological treatments for mild-to-severe AGA/FAGA compared)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 30 g over 6 months · 3 months · 14 days · 7 days. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Pumpkin Seed Oil (Cucurbita pepo), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (30 g) and re-evaluate efficacy after 6 months.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (20 Studies)

01
CLINICAL STUDY BioImpacts (2026) PMID: 42371524 ↗
Dutasteride-loaded nanostructured lipid carrier for androgenic alopecia treatment - An in vivo study.
Clinical Trial Synthesis 2026 Clinical Study published in BioImpacts. Key conclusion: Gamma-oryzanol (GO) is an anti-oxidant and anti-5-alpha reductase, which has been i
View Original PubMed Abstract ↓

INTRODUCTION: Androgenic alopecia (AGA) is the most common type of hair loss that occurs due to androgens, specially, dihydrotestosterone (DHT), and the 5-alpha reductase is the key enzyme to control AGA, as it is responsible for the conversion of testosterone to DHT, the more potent form of testosterone involved in the pathogenesis of AGA. Blockers of this enzyme suppress the conversion of androgens to DHT. Dutasteride is one of the 5-alpha reductase inhibitors and is frequently used as an anti-hair loss treatment. Gamma-oryzanol (GO) is an anti-oxidant and anti-5-alpha reductase, which has been i

02
META-ANALYSIS Frontiers in nutrition (2025) PMID: 41561175 ↗
Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis.
Clinical Trial Synthesis 2025 Meta-Analysis published in Frontiers in nutrition. Key conclusion: Dietary supplements, claimed to promote hair growth by inhibiting androgen pathways and improving the follicular microenvironment, have become an attractive adjunct for both clinicians and patients due to their low cost and ease of use.
View Original PubMed Abstract ↓

BACKGROUND: In recent years, androgenetic alopecia (AGA) has emerged as a significant public health concern due to its high prevalence and progressive nature. In addition to progressive scalp thinning and hair loss, patients often experience psychological distress and diminished quality of life. While standard treatments such as finasteride and minoxidil are effective, their side effects and adherence issues limit long-term use, making the exploration of safe and accessible intervention strategies essential. Dietary supplements, claimed to promote hair growth by inhibiting androgen pathways and improving the follicular microenvironment, have become an attractive adjunct for both clinicians and patients due to their low cost and ease of use. However, existing studies have limitations, including the diversity of supplements, small sample sizes, and the lack of direct comparisons among different supplements, making it unclear how they compare in terms of efficacy and safety. This study aims to use a network meta-analysis (NMA) to compare the effectiveness and safety of various dietary supplements based on outcomes such as hair density and terminal hair density, providing evidence-based support for clinical decision-making. METHODS: A systematic search was conducted in English-language databases such as PubMed, Cochrane Library, Embase, and Web of Science for randomized controlled trials (RCTs) investigating the use of dietary supplements for treating AGA. Stata 16.0 software was used for network meta-analysis, and Revman 5.4 software was utilized for evaluating study quality and bias risk; additionally, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework was applied to rate the certainty (quali

03
RANDOMIZED TRIAL (RCT) Journal of cosmetic dermatology (2025) PMID: 40853071 ↗
Impact of a Novel Dietary Supplement on Efficacy of Pharmacological Treatments for Androgenic Alopecia: A Real-Life, Multicenter, Randomized, Assessor-Blinded Trial on 225 Subjects.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Journal of cosmetic dermatology involving n = 225 participants. Key conclusion: RESULTS: The results indicated that oral supplementation significantly increased the clinical efficacy of pharmacological treatments for mild-to-severe AGA/FAGA compared
View Original PubMed Abstract ↓

BACKGROUND: Minoxidil and finasteride are currently the only FDA-approved pharmacological treatments for androgenic alopecia (AGA) and female androgenic alopecia (FAGA). However, substantial improvement is observed in no more than 20% of patients in the medium term. To enhance clinical responses, nonpharmacological dietary supplementation is often utilized. AIMS: This study evaluated the efficacy of a novel dietary supplement, AGA-P, which contains Serenoa repens extract, Cucurbita pepo extract, L-Cystine, and Vitamin C, in a multicenter, randomized, assessor-blinded, real-life trial alongside pharmacological treatments. The objective was to determine whether dietary supplementation could improve the clinical efficacy of minoxidil and finasteride. PATIENTS AND METHODS: A total of 225 subjects with AGA or FAGA (165 men, mean age 40 ± 14 years, range 18-74) were enrolled after obtaining informed consent. Inclusion criteria included male subjects over 18 years and postmenopausal women with mild to moderate AGA/FAGA, eligible for dietary and/or pharmacological treatment. Of these participants, 106 (24 women and 82 men) were assigned to receive pharmacological treatment plus dietary supplementation (one capsule daily; Group A), while 119 (36 women and 83 men) received drug treatment only (Group B). The pharmacological treatments consisted of topical minoxidil and oral finasteride in most cases. Treatment duration was 6 months. RESULTS: The results indicated that oral supplementation significantly increased the clinical efficacy of pharmacological treatments for mild-to-severe AGA/FAGA compared

04
CLINICAL STUDY Skin appendage disorders (2025) PMID: 40771449 ↗
Herbal Remedies for Hair Loss: A Review of Efficacy and Safety.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Skin appendage disorders. Key conclusion: These remedies were found to be effective in different conditions, including androgenetic alopecia, telogen effluvium, and alopecia areata, through various mechanisms of action, including 5α-reductase inhibition, increased microcapillary blood flow, antioxidant effects, and modul
View Original PubMed Abstract ↓

BACKGROUND: Hair loss (HL) is a prevalent condition worldwide; it can affect both males and females of different age groups. Despite the availability of many conventional treatment options, these might be linked to causing different side effects, leading to a growing interest in natural and herbal remedies (HRs). This review aims to investigate the efficacy and safety of various HRs for HL and examine the current scientific evidence behind them. SUMMARY: A literature search used several studies to identify relevant studies published up to March 2024. The search terms included HL, alopecia, HRs, and names of specific herbs such as rosemary, saw palmetto, onion juice, Korean red ginseng, pumpkin seed oil, azelaic acid, olive oil, coconut oil, henna, honey, rice bran extract, Ashwagandha, and amla. Studies have suggested potential benefits in promoting hair growth and treating various forms of HL. These remedies were found to be effective in different conditions, including androgenetic alopecia, telogen effluvium, and alopecia areata, through various mechanisms of action, including 5α-reductase inhibition, increased microcapillary blood flow, antioxidant effects, and modulation of the hair growth signaling pathways. KEY MESSAGES: Natural and HRs show promise in treating HL. However, many of these studies have limitations such as lack of long-term follow-up, small sample sizes, and short treatment durations. Due to this variation in the quality of evidence, further well-designed randomized trials with larger sample sizes are required to confirm the efficacy of these HRs. © 2025 S. Karger AG, Basel.

05
CLINICAL STUDY International journal of trichology (2025) PMID: 40654553 ↗
Topical Alternatives for Hair Loss: Beyond the Conventional.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in International journal of trichology. Key conclusion: These topicals with their less significant side effect profile may find their use as an add-on therapy or as an alternative in patients not tolerating standard therapies.
View Original PubMed Abstract ↓

Topical hair growth supplements in the form of hair growth serums, oils, and shampoos have flooded the cosmeceutical market. The gullible masses are targeted with sponsored marketing gimmicks through social media platforms. This review article brings to light the most hyped active ingredients or peptides in these products along with their clinical evidence available in the literature. The topical actives include Redensyl, Procapil, Capixyl, Baicapil, AnaGain, onion juice, coffee extract, saw palmetto extract, pumpkin seed oil (PSO), and rosemary oil. PubMed, Google Scholar, and Google databases were searched with the keywords: topical, hair growth, hair loss, and the respective active agents. Twenty-four relevant articles and technical files were extracted and reviewed. They have been studied mostly as combined formulations with other agents in randomized controlled trials or prospective cohort studies and have shown promising results. However, most of the studies have limited sample size, lack of comparison with standard therapies, nonuniformity between study groups, nondisclosure of the type of alopecia treated, and conflicts of interest. These topicals with their less significant side effect profile may find their use as an add-on therapy or as an alternative in patients not tolerating standard therapies. In this fast-growing commercialized world, it is imperative that we remain vigilant and understand the pros and cons of these products and ultimately guide our patients to the right track. Copyright: © 2025 International Journal of Trichology.

06
CLINICAL STUDY Journal of drugs in dermatology (2025) PMID: 40627570 ↗
Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions.
Clinical Trial Synthesis 2025 Clinical Study published in Journal of drugs in dermatology. Key conclusion: With increasing demand for non-pharmaceutical options, identifying natural, safe, and effective treatments for female hair loss is imperative.
View Original PubMed Abstract ↓

6. J Drugs Dermatol. 2025 Jul 1;24(7):659-662. doi: 10.36849/JDD.8763. Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. Leavitt A, Hawkins SD, Kindred C, Frey C, Gainers M, Grekin SK, Leavitt M. Female hair loss affects over 50% of postmenopausal women, with up to 40% of healthy women experiencing frontal/parietal hair loss, often beginning around reproductive age. Androgenetic alopecia is the most prevalent form of hair loss. Other types include alopecia areata, telogen effluvium, and scarring alopecias, such as lichen planopilaris and central centrifugal cicatricial alopecia. Hair loss can severely impact a woman's psychological well-being, yet treatments approved by the US Food and Drug Administration (FDA) remain limited to topical minoxidil and oral Janus kinase inhibitors. This manuscript reviews the multifaceted causes of female hair loss, hormonal imbalances, inflammation, nutrient deficiencies, aging, and oxidative stress, and explores non-pharmaceutical interventions. Saw palmetto, horsetail, and pumpkin seed oil, all of which inhibit 5α-reductase, show promise in promoting hair density and reducing hair follicle miniaturization. Curcumin has demonstrated anti-inflammatory effects, contributing to improved hair and scalp health. Nutritional deficiencies, particularly in iron, vitamin D, and essential minerals, also play a significant role in hair loss, underscoring the importance of a balanced diet and conservative supplementation. Avoiding excessive supplementation, especially with biotin, is recommended due to potential diagnostic test interferences. With increasing demand for non-pharmaceutical options, identifying natural, safe, and effective treatments for female hair loss is imperative. Further studies are needed to validate the efficacy and safety of these interventions.

07
CLINICAL STUDY Skin appendage disorders (2025) PMID: 40475103 ↗
Do Non-Prescription Products Help in Managing Androgenic Alopecia?
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Skin appendage disorders. Key conclusion: The available data demonstrate considerable improvements in one or more parameters: total hair density, terminal hair density and hair diameter.
View Original PubMed Abstract ↓

BACKGROUND: Androgenetic alopecia (AGA) is the most common cause of hair loss. Currently, approved medications for AGA are topical minoxidil and oral finasteride, both of which are prescription medications which may cause side effects. Non-prescription products such as herbal extracts and over-the-counter medications have limited evidence regarding safety and efficacy; however, they may be an alternative for patients unable or unwilling to use prescription medication. SUMMARY: This article reviews investigator-blinded, controlled clinical trials assessing the efficacy of non-prescription monotherapies in treating AGA. A total of 13 studies were included using procyanidin, cetirizine, caffeine, Oryza sativa bran, pumpkin seed oil, rosemary oil, saw palmetto, and watercress. The available data demonstrate considerable improvements in one or more parameters: total hair density, terminal hair density and hair diameter. Procyanidin and cetirizine were investigated in more investigator-blinded, randomized controlled trials than other agents. Minimal adverse events were observed; however, more robust clinical trial and long-term safety and efficacy data are warranted. KEY MESSAGE: Additional investigations through the conduct of high quality randomized, controlled trials with larger numbers of patients will help determine the effectiveness and safety of this class of compounds, either as monotherapy or as an addition to current pharmacological interventions. © 2024 The Author(s). Published by S. Karger AG, Basel.

08
RANDOMIZED TRIAL (RCT) Skin appendage disorders (2025) PMID: 39911983 ↗
Oral Supplementation with l-Cystine, Serenoa repens, Cucurbita pepo, and Pygeum africanum in Chronic Telogen Effluvium and Androgenetic Alopecia: A Double-Blind, Placebo-Controlled, Randomized Clinical Study.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Skin appendage disorders. Key conclusion: RESULTS: Hair density increased by 9.9 hairs/cm2 after 3 months and 12.3 hairs/cm2 after 6 months in the oral supplement group and it is statistically significant when compared to placebo.
View Original PubMed Abstract ↓

INTRODUCTION: Chronic telogen effluvium (TE) and androgenetic alopecia represent two prevalent forms of hair loss that can significantly impact individuals' quality of life. Insufficiency of essential micronutrients has been associated with hair loss. The objective of this study was to evaluate the safety and efficacy of an oral supplement containing l-Cystine, Serenoa repens, Cucurbita pepo, Pygeum africanum, vitamins, and micronutrients in chronic TE (CTE) and androgenetic alopecia (AGA). METHODS: Eighty patients of both sexes aged 18-60 years with CTE or AGA were randomized to receive one capsule daily of the oral supplement or placebo for 6 months. Dermatological evaluations, clinical pictures and phototrichograms were done at baseline, 3 months and 6 months. The overall hair volume and appearance were assessed before and after treatment as well as subject's self-assessment via standardized questionnaire. RESULTS: Hair density increased by 9.9 hairs/cm2 after 3 months and 12.3 hairs/cm2 after 6 months in the oral supplement group and it is statistically significant when compared to placebo. Overall hair volume after 1, 3, and 6 months is better in the supplement group than in the

09
CLINICAL STUDY Clinical, cosmetic and investigational dermatology (2024) PMID: 39524109 ↗
An Overview of Commonly Used Natural Alternatives for the Treatment of Androgenetic Alopecia, with Special Emphasis on Rosemary Oil.
Clinical Trial Synthesis 2024 Clinical Study published in Clinical, cosmetic and investigational dermatology. Key conclusion: This review article will not only provide a detailed background on this ancient herbal component but will additionally overview all other major herbal alternatives including peppermint oil, tea tree oil, green tea, pumpkin seed oil, saw palmetto, and lavender oil and will summari
View Original PubMed Abstract ↓

Androgenetic alopecia is a chronic dermatological condition in which genetically predisposed individuals undergo progressive hair loss secondary to the effects of circulating androgens. It has been well documented that dihydrotestosterone binds to the androgenic receptors prevalent in the scalp, thus inducing miniaturization of the hair follicle. To date, the only FDA approved medications for the treatment of androgenetic alopecia are finasteride and minoxidil. A plethora of studies have been conducted testing the efficacy of various herbal compounds, but additional research is needed to further establish the concrete efficacy of such natural remedies in treating androgenetic alopecia. Of late, rosemary oil has gained mass popularity as a promising natural alternative. This review article will not only provide a detailed background on this ancient herbal component but will additionally overview all other major herbal alternatives including peppermint oil, tea tree oil, green tea, pumpkin seed oil, saw palmetto, and lavender oil and will summarize the latest clinical studies, which have tested their efficacy for the management of androgenetic alopecia. © 2024 Bin Rubaian et al.

10
CLINICAL STUDY Expert opinion on emerging drugs (2024) PMID: 38666717 ↗
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia.
Clinical Trial Synthesis 2024 Clinical Study published in Expert opinion on emerging drugs. Key conclusion: AREAS COVERED: This article reviews the safety and effectiveness of well-known 5-α reductase inhibitors (5-ARIs) like finasteride and dutasteride, as well as the newer 5-ARIs, emerging androgen receptor antagonists (ARAs), and natural products such as saw palmetto and pumpkin see
View Original PubMed Abstract ↓

INTRODUCTION: Androgenetic alopecia (AGA) is the most prevalent cause of male hair loss, often requiring medical and/or surgical intervention. The US FDA has approved topical minoxidil and oral finasteride for male AGA treatment. However, some AGA patients fail to respond satisfactorily to these FDA-approved treatments and/or may experience side effects, based on their individual profiles. To mitigate the shortcomings of these treatments, researchers are now exploring alternative treatments such as newer 5-α reductase inhibitors (5-ARIs) and androgen receptor antagonists (ARAs). AREAS COVERED: This article reviews the safety and effectiveness of well-known 5-α reductase inhibitors (5-ARIs) like finasteride and dutasteride, as well as the newer 5-ARIs, emerging androgen receptor antagonists (ARAs), and natural products such as saw palmetto and pumpkin seed oil in the treatment of male AGA. EXPERT OPINION: Although several newer 5-ARIs, ARAs, and natural products have exhibited promise in clinical trials, additional research is essential to confirm their safety and efficacy in treating male AGA. Until additional evidence is available for these agents, the preferred treatment choices for male AGA are the FDA-approved treatments, topical minoxidil, and oral finasteride.

RELATED MONOGRAPHS

Related Monographs in This Category